Home › Chronic Lymphocytic Leukemia › Texas › Houston
Chronic Lymphocytic Leukemia clinical trials in Houston, TX
17 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RecruitingPhase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- UT MD Anderson Cancer Center, Houston
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
- Research Site, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- Md Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- The University of Texas MD Anderson Cancer Center, Houston
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
- Research Site, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
- MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RecruitingPhase 4
- University of Texas MD Anderson Cancer Center, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RecruitingPhase 4
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RecruitingPhase 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Cincinnati, OH14 studies
- Chicago, IL14 studies
- Nashville, TN13 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.